|
|
IMMEDIATE PRESS RELEASE |
| February 1, 2002 PST
John Piraino, Public Relations Rep. JPX, Inc., Encino, California 91316 Phone (818) 758-9081; E-Mail jp.com@att.net "TeleQUEST" – DP/Rx’s newest Internet Product Agoura Hills, California, February 1, 2002. Ira Chabrowe, DP/Rx’s Vice President of Product Development, announced today the inaugural Beta testing of DP/Rx’s TeleQUEST Internet product. This Internet-based Module, scheduled for final customer delivery in the 3rd quarter of 2002, was successfully installed for its beta testing at its facility in California, USA. Called TeleQUEST, this module enables processing a trial prescription to find out the results of a regular adjudication without recording the sale. TeleQUEST is an alternate procedure to the regular adjudication process of TeleCLAIM. It is launched for execution with a special F-key. This package complements the well-seasoned DP/Rx centerpiece product, called TeleCLAIM, which provides comprehensive adjudication processing of drug claims for HMOs, PPOs, Self-Insured Employers, PBMs and government subsidized programs. The benefit and value for this product is for drug plans that employ a "soft" formulary of optional Generic drug substitution for Brand drugs. A Brand drug, usually more expensive than its equivalent Generic, is initially designated as the trial drug and submitted to TeleQUEST for real-time adjudication. The response from the processing is the customary data of pass/fail, the ingredient cost used for reimbursement to the Pharmacy, the Co-Pay credit amount and Dispensing fee allowed for the Pharmacist. The "trial" processing does not record as a sale on this first submission. The TeleQUEST response also includes an alternative substitute drug that is cheaper (if one exists) in its message area. The pharmacist may then display the alternative cost, if any, for the Payer. Typically, a Generic substitute will be substantially cheaper in ingredient cost and Co-pay. If the substitute is selected by the payer, another F-key can switch the new drug designation as the primary order and the regular TeleCLAIM process is launched. That process is completed with a sale recorded and it also sends the POS device the corresponding sale particulars of the dispensed drug. If the payer decides to keep the original prescription drug designation, a third F-key is pressed to record the adjudication in TeleCLAIM for a completed transaction. Without TeleQUEST, an alternate drug is not provided and the likelihood is that the Brand drug is dispensed without another consideration. If the payer asks the pharmacist to recommend a substitute Generic, the Pharmacist must reverse the original claim and enter an entirely new alternative drug for adjudication (without knowing the specifics of the outcome). The outcome may be undesirable to the payer and the process of reversal and new order starts again. Thus, TeleQUEST also provides a significant advantage to the Pharmacist by replacing three possible transactions with two: 1st Rx, Reversal and the new Rx. By using TeleQUEST, the pharmacist gets the payer to see the alternate without request on the first pass. This approach will greatly enhance the possibilities of more conversions to Generics when the benefit plan provides savings for Generic utilization. For example, in these cases, the Brand might be 20% of $14 or $2.80. The alternative generic may cost $8 with a Co-pay of 10% or $0.80. The buyer may then be motivated to select the Generic by saving $2.00. TeleQUEST will be made available to TeleCLAIM users with a small monthly maintenance fee-licensing basis. For further information contact John Piriano. Be sure to visit our website: www.dprx.com
|
